Percutaneous CT-guided ablation of tumors will be reimbursed via Convention from November 2024 in Belgium

In July 2024, the National Institute for Health and Disability Insurance (INAMI-RIZIV) approved a new agreement (Convention) allowing reimbursement for percutaneous CT-guided ablation of renal, hepatic, pulmonary, and bone tumors. 

Specialized centers that meet certain eligibility criteria can apply to join the Convention before September 14, 2024. The list of approved centers will be published on the INAMI/RIZIV website.

The agreement will come into force on November 1, 2024, and will be valid until October 31, 2029.

The reimbursement will be available via new pseudonomenclature codes introduced by the Convention, for example, 587134-587145 “Percutaneous ablation of one or more renal tumors under CT guidance”. The following types of ablation are considered relevant: thermoablation (laser, radiofrequency, microwave, cryoablation) and electroporation.

Other pseudonomenclature codes were also introduced for anesthesiology services and multidisciplinary consultation.

Specific reimbursement conditions that must be fulfilled are also specified in the Convention.

See the full details in French here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.